A $2.5 billion pledge makes women's health a priority in Gates Foundation spend-down
Those are just two potential breakthroughs out of more than 40 the Gates Foundation intends to support through a five-year, $2.5 billion commitment on women's health research and development, more than triple the amount it has spent on women's health innovation over the past five years.
'Many of the most pressing conditions impacting women still remain understudied, underdiagnosed, and overlooked,' said Ru-fong Joanne Cheng, director of Women's Health Innovations at Gates.
A very small share of medical research funding supports the study of health specific to women, including gynecological and menstrual health, obstetric care, contraceptive innovation, sexually transmitted infections, and maternal health and nutrition, the foundation said. It cited a 2021 McKinsey and Company study that found 1% of all medical research, setting aside cancer research, goes toward women's health.
The foundation framed the commitment as part of its May announcement that it would spend down its assets over the next 20 years and concentrate much of its support on global health. While much of the research funded over the next five years will benefit women worldwide, the foundation said, the need is most acute in sub-Saharan Africa and Southeast Asia.
By devoting billions to women's health, the foundation has signaled it intends to continue to invest in the cause following the 2024 departure of Melinda French Gates, who led the foundation's support of girls' and women's health. Since her divorce from Bill Gates, French Gates has committed more than $1 billion to improve women's physical and mental health, provide more economic opportunity to women, and increase their political sway.
The announcement follows a U.S. pullback of support for global maternal health programs during the first seven months of the Trump administration.
The shuttering of the U.S. Agency for International Development and program reductions at the Centers for Disease Control have sunset programs focused on women's health. According to a March internal USAID memo, the agency's closure will stop services for 16.8 million pregnant women annually.
In April, the World Health Organization said that the 40 percent decline in maternal deaths from 2000 to 2023 has been put at risk because of aid cuts.
'We need both innovation and delivery'
While the foundation continues to focus on the delivery of health care globally in an era of governmental retreat, the $2.5 billion will focus squarely on research needed to save lives, Anita Zaidi, president of Gates's Gender Equality Division, said on a press call Monday to discuss the announcement.
'This is an innovation-focused announcement,' she said. 'We need both innovation and delivery.'
It's important to remember that the U.S. Food and Drug Administration has only been required to test novel drugs on women in clinical trials since 1993, and many tests are still only done on men, said Katy Brodsky Falco, founder of the Foundation for Women's Health, which plans to make $5 million in research grants this year.
With Gates getting behind research and development of women's health with such a large commitment, others may follow, Brodsky Falco said.
'Hopefully it will bring the issue to the top of the conversation among private donors and family foundations, even if they otherwise haven't supported this type of work,' she said.
Moses Obimbo Madadi, professor at the University of Nairobi, noted that postpartum hemorrhaging causes about 3,000 deaths annually in Kenya. If men were the victims, he said, a G7 conference would be called to find a solution, but research on the subject has largely been ignored because it claims the lives of women.
'We've treated this as a peripheral issue other than making it a centerpiece of our research,' he said, calling the Gates commitment a 'very good starting point.'
_____
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
17 hours ago
- Globe and Mail
How to tell the difference between stress and burnout
This is the weekly Work Life newsletter. If you are interested in more careers-related content, sign up to receive it in your inbox. If you've ever chalked up your exhaustion to just 'a rough week,' you might want to look closer. Burnout isn't always the dramatic crash we imagine. It often starts subtly, like a slow leak in your energy reserves, and if you're not paying attention, it can drain you completely. 'One of the biggest misconceptions about burnout is that it hits you all at once,' says Sharon Grossman, a psychologist, executive coach and author of The Burnout Solution: 7 Steps from Exhausted to Extraordinary. 'In reality, it creeps in gradually.' Dr. Grossman says early signs are easy to overlook or dismiss. Persistent fatigue, trouble focusing or snapping at coworkers may seem like small irritants, but they often signal something deeper. 'Many dismiss these as 'just being tired' or 'having a bad week,'' she says. 'But these can actually be early indicators that your energy tank is running on empty.' And when your coping resources are chronically depleted, burnout doesn't wait for a formal invitation. One reason burnout is so hard to pin down is that it shows up differently for everyone. 'For some of my clients, it shows up as emotional exhaustion. They are dragging through the day, both physically and mentally,' Ms Grossman says. 'For others, it's cynicism or detachment, where they stop caring about work they once loved.' Even high performers aren't immune. In fact, they're often more vulnerable. 'I've seen high achievers become hyper-critical of themselves, feel like they're failing even when they're performing and start questioning their worth,' she says. Dr. Grossman recalls experiencing burnout personally as a loss of meaning in her work. 'When I stopped feeling excited about my sessions and started just going through the motions, I knew something had to shift.' Burnout doesn't always look like collapse. Sometimes, it's the slow grind of pushing through until you break. The tricky part? Stress and burnout can feel similar but they require different responses. 'Stress is situational. It has a clear beginning and end,' says Dr. Grossman. 'Burnout, on the other hand, is chronic. It doesn't let up, even when circumstances improve.' If taking a vacation or stepping away from work doesn't bring relief, that's a red flag. So is emotional numbness or a sense that your efforts no longer matter. 'It's when stress stops being energizing and starts feeling soul-crushing,' she says. 'If you're feeling a lack of efficacy – like no matter how hard you try, you're not making progress – that's another hallmark of burnout.' To catch burnout early, Dr. Grossman recommends building emotional intelligence. She calls self-awareness 'your first line of defense.' In her book, one of the foundational tools she shares is the 'energy audit.' 'Ask yourself: What's draining me? What's fueling me?' she says. Journaling, mindfulness and monitoring your self-talk are also simple but powerful strategies. Recognizing and regulating your emotions, setting healthy boundaries and having the emotional literacy to speak up are key, she says. Recovery also depends on those same skills. 'It helps you reconnect with your values, navigate tough conversations and rebuild your confidence.' In a culture that rewards overworking, understanding the early signs of burnout and acting on them is essential. Stay tuned for part two next week, where I share insights from Dr. Grossman on what steps to take after you've identified burnout. 74 per cent That's how many workers report feeling anxious upon returning to work after vacation, according to new data from global recruitment consultancy Robert Walters. Read more Workplaces tend to celebrate beginnings while overlooking endings, even though endings are crucial for emotional health and organizational trust. Here, Harvey Schachter pulls out key points from the book Good Bye: Leading change better by attending to endings, to showcase how acknowledging endings not only prevents lingering negativity, but also creates space to learn from experiences. Read more 'My premedical adviser, I'm just like, you're not helping me that much. On social media, it feels the same as if I was asking a friend who did what I'm doing, but a year or two ago. They are in the loop and their advice is way more direct,' says 22-year-old Olivia Sotos, an aspiring doctor who graduated from college just over a month ago. This article looks at how some young job seekers say traditional career advice from parents and school counselors feels outdated and they're now looking to successful young professionals on social media for advice and inspiration. Read more OpenAI is still leading the AI race, but early stumbles with GPT-5 are starting to raise eyebrows. Since the launch, users have flagged basic mistakes, a drop in quality when it comes to tone and growing frustration over a 200-question weekly cap. Chief executive officer Sam Altman has publicly acknowledged the feedback and says improvements are on the way. But with fast-moving challengers such as Anthropic picking up steam, OpenAI could lose their lead. Read more
CBC
19 hours ago
- CBC
Study shows women who've been stalked at higher risk of heart disease: Dr. Peter Lin
D. Peter Lin talks about a new study out of Harvard University that looks at links between heart disease and those who have experienced stalking.
Globe and Mail
2 days ago
- Globe and Mail
2 Top Dividend Stocks to Buy on the Dip
Key Points Pfizer's pipeline in oncology, combined with its cost-cutting initiatives, could help it bounce back. Merck could move beyond Keytruda thanks to newer approvals and a novel formulation of the medicine. Both companies have increased their dividends at a decent rate over the past five years. 10 stocks we like better than Pfizer › Dividend stocks are a great investment choice for many reasons. Buying on the dip is even better, provided, of course, they have the means to bounce back. Investors looking for companies that fit this profile should strongly consider Pfizer (NYSE: PFE) and Merck (NYSE: MRK). These two market leaders have lagged broader equities over the trailing-12-month period, but for those focused on the long game, they still look attractive. Here's the rundown. 1. Pfizer Over the past few years, Pfizer has dealt with worsening financial results and stiff competition for some products. It also faces the prospect of losing patent protection for others; these include Eliquis, an anticoagulant that is one of its top-selling drugs, and Xtandi, a cancer treatment. Both will lose their patents in the U.S. within the next few years. These challenges have led to terrible stock-market performance. However, the sell-off may have gone too far. At current levels, Pfizer's shares look attractive. One reason the company should bounce back and continue to deliver strong returns over the long run is its deep pipeline, particularly in oncology, one of the largest therapeutic areas in the industry. Pfizer currently has five blockbuster cancer medicines, and plans to raise that number to eight by 2030. Pfizer has exciting candidates in other areas as well, and in recent years has earned approval for several new products. Though these aren't yet meaningfully contributing to its top-line growth, they should do so eventually as they earn label expansion. The company's vaccine for respiratory syncytial virus (RSV), Abrysvo, generated $143 million in sales in the second quarter, which isn't bad for a product approved in 2023. It also recently earned a label expansion in Europe for adults age 18 to 59 (it was previously indicated for those 60 and older). Pfizer should make progress with Abrysvo and other newer launches. The company has also been reducing expenses. These initiatives were likely partly responsible for Pfizer's earnings beat during the second quarter. Management intends to achieve $4.5 billion in net cost savings this year and pursue further reductions in the years ahead, efforts that should help improve profitability. Pfizer is a solid dividend stock. Its forward yield currently tops 7%, and the company has increased its payouts by 19.5% in the past five years. While the stock may take some time to recover, Pfizer could be an excellent long-term investment for income-seeking investors. 2. Merck Merck is facing several issues, none more important than increased competition for its best-selling drug, cancer medicine Keytruda, and an upcoming patent cliff in 2028 for the medicine. Also, the company's second-quarter results were not strong: Revenue declined by 2% year over year to $15.8 billion, while adjusted earnings per share declined by 7% to $2.13. However, there were some bright spots for the company. Most notably, Winrevair -- one of its newest launches, which earned approval last year -- reported sales of $336 million. Winrevair is a therapy for pulmonary arterial hypertension with a new mechanism of action. It should become a blockbuster relatively soon. Merck's business in animal health -- where it's one of the leaders -- also performed well, with sales from that segment rising by 11% year over year to $1.6 billion in the second quarter. Meanwhile, Merck has some exciting pipeline candidates that should help it overcome Keytruda-related challenges. One of them is a subcutaneous version of Keytruda, which has already aced phase 3 studies and will help extend the medicine's patent protection. Merck has also significantly improved its pipeline in recent years thanks to licensing agreements. Its candidates include promising cancer products and weight loss medicines. Just as Winrevair appears to be a major success, Merck is also likely to develop innovative therapies that will mitigate potential Keytruda-related revenue losses. So, despite recent setbacks, the business could bounce back given Merck's history of innovation. Turning to Merck's dividend program, the company now offers a forward yield of 4.1%, with its dividends increasing by 39% over the past five years. The stock remains a good pick for dividend seekers. Should you invest $1,000 in Pfizer right now? Before you buy stock in Pfizer, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Pfizer wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025
